Search

Takeda Pharmaceutical Co Ltd ADR

Suletud

SektorTervishoid

20.75 -0.62

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

20.78

Max

20.95

Põhinäitajad

By Trading Economics

Sissetulek

138B

113B

Müük

105B

1.2T

P/E

Sektori keskmine

42.622

50.373

Aktsiakasum

0.48

Dividenditootlus

3.05

Kasumimarginaal

9.279

Töötajad

47,029

EBITDA

231B

389B

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+106.77% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

3.05%

2.12%

Turustatistika

By TradingEconomics

Turukapital

9.6B

65B

Eelmine avamishind

21.37

Eelmine sulgemishind

20.75

Takeda Pharmaceutical Co Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. nov 2026, 23:56 UTC

Social Media
News

Roku, Inc. reported Q3 2026 earnings per share of $1.20 and revenue of $1.5 billion, exceeding analyst estimates, but did not provide forward guidance.

2. nov 2026, 23:51 UTC

Social Media
News
Correlated Moves

Ichor Holdings reported Q3 2026 adjusted EPS of $0.63, above the $0.45 consensus, and provided positive Q4 guidance of $0.65 to $0.75.

2. nov 2026, 23:41 UTC

News

Stifel Financial Corp. declares a quarterly cash dividend of $0.34 per share, payable December 15, 2026, to shareholders of record as of December 1, 2026.

2. nov 2026, 23:41 UTC

News

Rivian Automotive, Inc. is seeing a modest increase in after-market trading, supported by higher overall market trends and a trading volume of 64.3 million shares.

2. nov 2026, 23:41 UTC

News

Camping World Holdings Inc reported a Q3 net loss of $320.1 million and missed adjusted EPS expectations, prompting a sharp decline in after-market trading.

2. nov 2026, 23:31 UTC

News

EverQuote, Inc. reported Q3 revenue of $218.1 million, exceeding estimates, and expects Q4 revenue between $213 million and $223 million.

2. nov 2026, 23:26 UTC

News

Amgen Inc. will release its third quarter 2026 financial results on November 3, 2026, after U.S. markets close, followed by a conference call.

2. nov 2026, 23:21 UTC

News

Capital Southwest Corporation reported Q2 pre-tax net investment income of $37.2 million and net asset value per share of $16.64, despite $13.4 million in investment losses.

2. nov 2026, 23:21 UTC

Social Media
News
Correlated Moves

Intel Corp is trading higher in after-market hours following a quarterly report that included a downward guidance adjustment.

2. nov 2026, 23:21 UTC

Social Media
News

Oracle Corporation plans to raise $20 billion through stock and bond offerings to finance its artificial intelligence infrastructure expansion, according to regulatory filings.

2. nov 2026, 23:21 UTC

News

Celsius Holdings faces a class action lawsuit from Pomerantz LLP over alleged misrepresentation of safety regarding its Alani Nu energy drinks.

2. nov 2026, 23:21 UTC

News
Event

Douglas Dynamics reports record Q3 results with net sales up 35% to $218.0M and net income rising 166% to $21.2M, despite missing revenue expectations.

2. nov 2026, 23:21 UTC

Correlated Moves
Social Media
News

Lumentum Holdings Inc. shares rose during after-market hours, following Fabrinet's strong fiscal Q1 results and positive revenue guidance for Q2.

2. nov 2026, 23:21 UTC

News

Keysight Technologies appoints Jason Kary as Chief Financial Officer, effective December 18, 2026, while maintaining its outlook for Q4 fiscal 2026.

2. nov 2026, 23:16 UTC

News

Leidos Holdings plans to enhance its supply chain for long-range cruise missiles, with initial deliveries expected in 2027 under a framework agreement with the Department of War.

2. nov 2026, 23:16 UTC

News

Jazz Pharmaceuticals reports record Q3 revenues of $1.2 billion and raises full-year guidance to $4.775 billion to $4.850 billion despite a net loss of $483.4 million.

2. nov 2026, 23:16 UTC

News

Thermo Fisher Scientific Inc. has a market capitalization of $262.95 billion, with shares advancing in after-market trading following earlier declines.

2. nov 2026, 23:16 UTC

News

Enovix Corporation filed a registration statement with the SEC to offer up to $500 million in mixed securities to enhance financial flexibility for growth initiatives.

2. nov 2026, 23:12 UTC

Social Media
Correlated Moves
News

Advanced Micro Devices, Inc. is advancing in after-market trading, influenced by Aehr Test Systems' record revenue and raised outlook for fiscal 2027.

2. nov 2026, 23:11 UTC

News

HealthStream, Inc. reported Q3 revenues of $83.3 million and EPS of $0.18, raising full-year 2026 revenue guidance to $331 million to $333 million.

2. nov 2026, 23:06 UTC

News

Public Service Enterprise Group shares traded modestly lower in after-market hours, retracing from earlier gains amid a day of unusual volatility.

2. nov 2026, 23:06 UTC

News

Replimune Group, Inc. will meet with Cantor on November 4 in New York and November 5 in Boston to discuss its strategic direction.

2. nov 2026, 23:06 UTC

Social Media
News

Match Group reported Q3 revenue of $891.2 million, below the $892.5 million estimate, and guided for Q4 revenue of $865 million to $875 million.

2. nov 2026, 23:06 UTC

News

UBS maintains Buy rating on Arch Capital Group Ltd. and raises price target to $125 in a report published today.

2. nov 2026, 23:06 UTC

News

AbbVie Inc. gains after director Jennifer L. Davis resigns to become CEO at Align Technology; UBS raises price target to $295 while maintaining Neutral rating.

2. nov 2026, 23:06 UTC

Social Media
News

Diamondback Energy reported strong third-quarter results, with adjusted EPS of $5.86 and revenues of $5.43 billion, while raising its base dividend to $1.18 per share.

2. nov 2026, 23:06 UTC

Social Media
News

Salesforce, Inc. has signed a definitive agreement to acquire Cresta, enhancing its Service Cloud with voice-based AI agents for customer service operations.

2. nov 2026, 23:06 UTC

News

UBS maintains Neutral rating on American Express and raises price target to $346, following the company's increased third-quarter net income and raised earnings guidance.

2. nov 2026, 23:06 UTC

Social Media
News

Marvell Technology, Inc. is trading higher in after-market hours following its $115 billion acquisition of Lumentum Holdings, aimed at enhancing AI growth.

2. nov 2026, 23:02 UTC

News

Regeneron Pharmaceuticals plans to webcast management participation at upcoming investor conferences, including Jefferies on November 17 and Evercore on December 1, 2026.

Võrdlus sarnastega

Hinnamuutus

Takeda Pharmaceutical Co Ltd ADR Prognoos

Hinnasiht

By TipRanks

106.77% tõus

12 kuu keskmine prognoos

Keskmine 43.153 USD  106.77%

Kõrge 43.153 USD

Madal 43.153 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Takeda Pharmaceutical Co Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
help-icon Live chat